Novoeight (Turoctocog Alfa)

Turoctocog alfa, the active ingredient in Novoeight, is a recombinant factor VIII presented as a solution for injection for intravenous use. It treats hemophilia A (congenital factor VIII deficiency) in patients requiring replacement therapy. GNH USA supplies Novoeight as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Novoeight is a recombinant factor VIII used in the intrinsic coagulation pathway to manage hemophilia A. - Hemophilia A (congenital factor VIII deficiency): provides replacement of factor VIII to prevent or control bleeding episodes. - Surgical prophylaxis in hemophilia A patients: maintains hemostasis during operative procedures. - Prevention of bleeding episodes in hemophilia A: reduces the frequency of spontaneous bleeds.

Novoeight may be associated with several adverse reactions. Common Side Effects: - Injection site pain or erythema - Headache - Fever - Arthralgia - Nausea - Fatigue Serious or Rare Side Effects: - Development of factor VIII inhibitors (neutralizing antibodies) - Anaphylactic or severe allergic reactions - Thromboembolic events - Severe hypotension - Hemolysis

Novoeight requires careful clinical monitoring and adherence to handling guidelines. - Dose individualized: dosing is determined by the prescribing clinician based on patient weight, baseline factor VIII level, and clinical need. - Monitor for inhibitors: regular testing for development of factor VIII inhibitors is recommended. - Assess bleeding risk: evaluate before invasive procedures or surgery. - Use with caution in patients with a history of thrombosis. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Novoeight may interact with other agents affecting coagulation. Major Interactions (Avoid): - Antifibrinolytics (e.g., tranexamic acid) may increase thrombosis risk when combined with high factor VIII levels. - Immune tolerance induction agents may alter inhibitor development. Moderate Interactions (Monitor Closely): - Concomitant use of other clotting factor products may affect dosing requirements. - Immunosuppressive therapies may modify inhibitor risk. - Certain antibiotics (e.g., beta‑lactams) may rarely affect infusion reactions.